## JAPY REC'S PCTIPTO 10 JUL 2006

FORM PTO-1390(modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER REV 10-951 30394 TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (IF KNOWN), SEE 32 CFR -DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING 10/585695 A FILING UNDER 35 U.S.C., 371 PRIORITY DATE CLAIMED INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PCT/IL2005/000028 January 9, 2005 January 9, 2004 TITLE OF INVENTION COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH AMYLOID FIBRIL FORMATION APPLICANT(S) FOR DO/EO/US (1) Hermona SOREQ; (2) Sophie DIAMANT; Applicant herewith submits to the United States Designated/Elected Office (DO/EO.US) the following items and other information: 1. E This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371 3. Digital This is an express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. A copy of the International Application as filed (35 U.S.C. 371(3)(2) a. is transmitted herewith (required only if not transmitted by the International Bureau). b. 🗵 has been transmitted by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. A translation of the International Application into English (35 U.S.C. 371(3)(2). 7. A copy of the International Search Report (PCT/ISA/210). 8. 

Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3) a.  $\square$  are transmitted herewith (required only if not transmitted by the International Bureau). b.  $\square$  have been transmitted by the International Bureau. c. | have not been made; however, the time limit for making such amendments has NOT expired. d. 

have not been made and will not be made. 9. A translation of the amendments to the claims under PCT Article 19(35 U.S.C. 371(c)(3)). 10. An un-executed oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 11. A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)5)). Items 13 to 18 below concern document(s) of information included: 13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 16. A substitute specification. 17. A change of power of attorney and/or address letter. 18. Certificate of Mailing by Express Mail 19. E The sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing 20. Other items or information: PCT REQUEST; APPLICATION DATA SHEET; PETITION TO ACCEPT COLOR DRAWINGS/PHOTOGRAPHS; SEQUENCE LISTING ON DUPLICATE COMPACT DISC COPIES AND CRF COPIES 21. 🗷 75 pages of specification (including Abstract page) 22. **2** 6 sheets of drawings 23. pages of sequence listing 24. 2 81 total pages